This page synthesizes therapeutic approaches for neurodegenerative diseases, ranking them by clinical evidence strength, mechanism validation, and development pipeline completeness. These rankings integrate data from investment activity, clinical trial outcomes, and mechanistic evidence to identify the most promising therapeutic directions.
Ranking criteria:
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|---|---|---|---|---|---|---|
| 1 | Lecanemab (monoclonal antibody) | 95 | 90 | 85 | 90.5 | Approved |
| 2 | Donanemab (monoclonal antibody) | 90 | 85 | 80 | 85.5 | Approved |
| 3 | Aβ vaccine (ACC-001) | 60 | 80 | 70 | 70.0 | Phase 2 |
| 4 | BACE1 inhibitors (umbrecenestat) | 40 | 70 | 30 | 47.0 | Halted |
| 5 | γ-secretase modulators | 30 | 60 | 40 | 43.0 | Phase 1 |
Evidence Synthesis: The approval of lecanemab and donanemab represents an unprecedented validation of the amyloid cascade hypothesis[1]. However, the modest clinical effect size (27% slowing of decline) suggests amyloid clearance alone is insufficient for full disease modification.
Key References:
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|---|---|---|---|---|---|---|
| 1 | Tau immunotherapy (gosuranemab) | 70 | 85 | 75 | 76.5 | Phase 3 |
| 2 | Tau aggregation inhibitors (MCC) | 55 | 75 | 60 | 63.5 | Phase 2 |
| 3 | Tau kinase inhibitors (GSK-3β) | 40 | 65 | 45 | 50.0 | Phase 1 |
| 4 | O-GlcNAcase inhibitors | 35 | 60 | 40 | 45.0 | Phase 1 |
Evidence Synthesis: Tau pathology shows stronger correlation with cognitive decline than amyloid[2]. The failure of several tau immunotherapy programs (gosuranemab, semorinemab) has raised questions about tau as a therapeutic target.
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|---|---|---|---|---|---|---|
| 1 | GLP-1 receptor agonists | 75 | 70 | 80 | 75.5 | Phase 3 |
| 2 | Neurotrophic factors (BDNF) | 45 | 80 | 40 | 55.5 | Phase 1 |
| 3 | Anti-oxidative stress | 50 | 65 | 50 | 55.0 | Phase 2 |
| 4 | Metal chelation therapy | 35 | 55 | 30 | 40.5 | Phase 2 |
Evidence Synthesis: GLP-1 agonists (liraglutide, semaglutide) show promise in AD clinical trials with effects on neuroinflammation and synaptic function[3].
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|---|---|---|---|---|---|---|
| 1 | α-syn immunotherapy (prasinezumab) | 65 | 80 | 70 | 71.5 | Phase 2 |
| 2 | Small molecule aggregation inhibitors | 50 | 75 | 55 | 60.5 | Phase 1 |
| 3 | Gene therapy (AAV-A53T) | 40 | 70 | 35 | 48.5 | Preclinical |
| 4 | RNA targeting (ASO) | 35 | 65 | 40 | 47.0 | Phase 1 |
Evidence Synthesis: The failure of pasAD and related trials has shifted focus to earlier intervention and biomarker-driven patient selection[4].
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|---|---|---|---|---|---|---|
| 1 | LRRK2 kinase inhibitors (DNL151) | 60 | 85 | 65 | 70.5 | Phase 2 |
| 2 | LRRK2 ASO therapy | 40 | 70 | 45 | 52.0 | Phase 1 |
| 3 | LRRK2 gene editing | 25 | 55 | 20 | 34.0 | Preclinical |
Evidence Synthesis: LRRK2 inhibitors show promise in PD, with genetic validation from G2019S mutation[5]. However, the role of LRRK2 in sporadic PD remains unclear.
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|---|---|---|---|---|---|---|
| 1 | TFEB activators | 45 | 75 | 55 | 58.5 | Phase 1 |
| 2 | Mitophagy enhancers (urolithin A) | 55 | 70 | 60 | 61.5 | Phase 3 |
| 3 | CoQ10 supplementation | 50 | 60 | 45 | 52.0 | Phase 3 |
| 4 | PINK1/Parkin activators | 30 | 65 | 25 | 40.5 | Preclinical |
Evidence Synthesis: Mitochondrial dysfunction is a central mechanism in PD, but clinical translation has been challenging[6].
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|---|---|---|---|---|---|---|
| 1 | Tofersen (SOD1 ASO) | 85 | 95 | 80 | 87.0 | Approved |
| 2 | C9orf72 ASO | 65 | 90 | 60 | 72.0 | Phase 3 |
| 3 | FUS gene therapy | 45 | 75 | 40 | 54.0 | Phase 1 |
| 4 | ATXN2 ASO | 50 | 70 | 45 | 55.5 | Phase 1 |
Evidence Synthesis: Tofersen approval validates gene-targeting approaches in ALS[7]. The challenge remains that by the time symptoms appear, significant neuronal loss has already occurred.
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|---|---|---|---|---|---|---|
| 1 | Riluzole (glutamate modulation) | 70 | 55 | 60 | 62.5 | Approved |
| 2 | Edaravone (anti-oxidant) | 65 | 50 | 55 | 57.5 | Approved |
| 3 | Antisense SOD1 gene therapy | 80 | 90 | 75 | 82.0 | Approved |
| 4 | Stem cell therapy | 35 | 60 | 30 | 42.0 | Phase 1 |
| Rank | Mechanism | AD Score | PD Score | ALS Score | Avg | Priority |
|---|---|---|---|---|---|---|
| 1 | TREM2 modulation | 80 | 70 | 60 | 70 | High |
| 2 | NLRP3 inhibition | 65 | 70 | 65 | 67 | High |
| 3 | CSF1R blockade | 60 | 55 | 70 | 62 | Medium |
| 4 | Complement inhibition | 55 | 50 | 60 | 55 | Medium |
Evidence Synthesis: Microglial modulation represents a promising cross-disease approach, particularly TREM2 variants showing strong AD genetic validation[8].
| Rank | Mechanism | AD Score | PD Score | ALS Score | Avg | Priority |
|---|---|---|---|---|---|---|
| 1 | Autophagy induction (TFEB) | 70 | 75 | 65 | 70 | High |
| 2 | Proteasome enhancement | 55 | 60 | 70 | 62 | Medium |
| 3 | Chaperone modulation | 50 | 65 | 60 | 58 | Medium |
| 4 | Unfolded protein response | 45 | 50 | 55 | 50 | Low |
Based on pipeline activity, clinical success rates, and mechanism validation:
van Dyck et al. Lecanemab in Early Alzheimer's Disease (2023). 2023. ↩︎
Murphy et al. Tau as a Therapeutic Target (2023). 2023. ↩︎
Femminella et al. GLP-1 Agonists in Alzheimer's Disease (2023). 2023. ↩︎
Pajares et al. Alpha-Synuclein Aggregation in Parkinson's Disease (2020). 2020. ↩︎
Cook et al. LRRK2 Kinase Inhibitors for Parkinson's Disease (2023). 2023. ↩︎
Borsche et al. Mitochondrial Dysfunction in Parkinson's Disease (2021). 2021. ↩︎
Miller et al. Tofersen in SOD1-ALS (2023). 2023. ↩︎
Deczkowska et al. TREM2 and Neurodegeneration (2023). 2023. ↩︎